|
Carcinosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 250 patients were enrolled, and the concordance rates were 56% for endometrioid adenocarcinoma grade 1 (EMG1), 67% for EMG2, 67% for EMG3, 82% for carcinosarcoma, 71% for serous carcinoma, and 67% for clear cell carcinoma.
|
30826751 |
2019 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
Seven days after stroke, the following treatments were initiated and continued for 3 weeks: forced limb use in constraint-induced movement therapy rats (constraint-induced movement therapy group), intraperitoneal infusion of fasudil (a ROCK inhibitor) in fasudil rats (fasudil group), or lateral ventricular injection of NEP1-40 (a specific antagonist of the Nogo-66 receptor) in NEP1-40 rats (NEP1-40 group).
|
31169192 |
2019 |
|
Adenocarcinoma, Clear Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 250 patients were enrolled, and the concordance rates were 56% for endometrioid adenocarcinoma grade 1 (EMG1), 67% for EMG2, 67% for EMG3, 82% for carcinosarcoma, 71% for serous carcinoma, and 67% for clear cell carcinoma.
|
30826751 |
2019 |
|
Carcinoma, Endometrioid
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A total of 250 patients were enrolled, and the concordance rates were 56% for endometrioid adenocarcinoma grade 1 (EMG1), 67% for EMG2, 67% for EMG3, 82% for carcinosarcoma, 71% for serous carcinoma, and 67% for clear cell carcinoma.
|
30826751 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry and western blot assay results showed that, at 2 weeks after middle cerebral artery occlusion, expression levels of RhoA and ROCK were lower in the ischemic boundary zone in rats treated with NEP1-40 compared with rats treated with ischemia/reperfusion or constraint-induced movement therapy alone.
|
31169192 |
2019 |
|
Adenocarcinoma, Endometrioid
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A total of 250 patients were enrolled, and the concordance rates were 56% for endometrioid adenocarcinoma grade 1 (EMG1), 67% for EMG2, 67% for EMG3, 82% for carcinosarcoma, 71% for serous carcinoma, and 67% for clear cell carcinoma.
|
30826751 |
2019 |
|
Neural Tube Defects
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Embryos homozygous for the mutation in Emg1 were small for gestational age with neural tube defects, and died between embryonic days 8.5 and 12.5.
|
25708872 |
2015 |
|
Scleroderma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three SSU processome components and their related human diseases will be explored in this review: hUTP4/Cirhin, implicated in North American Indian childhood cirrhosis (NAIC); UTP14, implicated in infertility, ovarian cancer, and scleroderma; and EMG1, implicated in Bowen-Conradi syndrome (BCS).
|
24240090 |
2014 |
|
Systemic Scleroderma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three SSU processome components and their related human diseases will be explored in this review: hUTP4/Cirhin, implicated in North American Indian childhood cirrhosis (NAIC); UTP14, implicated in infertility, ovarian cancer, and scleroderma; and EMG1, implicated in Bowen-Conradi syndrome (BCS).
|
24240090 |
2014 |
|
NORTH AMERICAN INDIAN CHILDHOOD CIRRHOSIS
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three SSU processome components and their related human diseases will be explored in this review: hUTP4/Cirhin, implicated in North American Indian childhood cirrhosis (NAIC); UTP14, implicated in infertility, ovarian cancer, and scleroderma; and EMG1, implicated in Bowen-Conradi syndrome (BCS).
|
24240090 |
2014 |
|
Developmental Disabilities
|
0.010 |
GeneticVariation
|
group |
BEFREE |
A mutation in the human EMG1 homolog causes Bowen-Conradi syndrome (BCS), a developmental disorder characterized by severe growth failure and psychomotor retardation leading to death in early childhood.
|
20858271 |
2010 |
|
Failure to Thrive
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A mutation in the human EMG1 homolog causes Bowen-Conradi syndrome (BCS), a developmental disorder characterized by severe growth failure and psychomotor retardation leading to death in early childhood.
|
20858271 |
2010 |
|
Growth failure
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
A mutation in the human EMG1 homolog causes Bowen-Conradi syndrome (BCS), a developmental disorder characterized by severe growth failure and psychomotor retardation leading to death in early childhood.
|
20858271 |
2010 |
|
Ewings sarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
ATCC. www.lgcstandards-atcc.org/Products/All/CRL-1441.aspx?geo_country=it Memorial Sloan Kettering Cancer Cancer. https://www.mskcc.org/research-advantage/support/technology/tangiblematerial/sk-nep-1-human-ewing-sarcoma-cell-line.
|
30481065 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
LBH589 had a significant effect and few side effects on SK-NEP-1 xenograft tumors.
|
26176219 |
2015 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
SK-NEP-1 and Rh1 are Ewing family tumor lines.
|
17154184 |
2008 |
|
Ewings sarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We describe the use of gene expression profiling to show that SK-NEP-1, a cell line previously thought to represent anaplastic Wilms tumor, is instead related to Ewing sarcoma.
|
17154184 |
2008 |
|
Nephroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
With over-expression and knockdown of miR-190b in WT-derived cell line SK-NEP-1, we next studied cell proliferation, cell circle, apoptosis, invasion and migration abilities change caused by miR-190b ectopic expression.
|
29509256 |
2018 |
|
Childhood Kidney Wilms Tumor
|
0.040 |
Biomarker
|
disease |
BEFREE |
With over-expression and knockdown of miR-190b in WT-derived cell line SK-NEP-1, we next studied cell proliferation, cell circle, apoptosis, invasion and migration abilities change caused by miR-190b ectopic expression.
|
29509256 |
2018 |
|
Nephroblastoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Carboplatin-based Nanomedicine to Enhance the Anticancer Effect in SK-NEP-1 WilmsꞌTumor Cells.
|
29552042 |
2017 |
|
Childhood Kidney Wilms Tumor
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Carboplatin-based Nanomedicine to Enhance the Anticancer Effect in SK-NEP-1 WilmsꞌTumor Cells.
|
29552042 |
2017 |
|
Nephroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We describe the use of gene expression profiling to show that SK-NEP-1, a cell line previously thought to represent anaplastic Wilms tumor, is instead related to Ewing sarcoma.
|
17154184 |
2008 |
|
Childhood Kidney Wilms Tumor
|
0.040 |
Biomarker
|
disease |
BEFREE |
We describe the use of gene expression profiling to show that SK-NEP-1, a cell line previously thought to represent anaplastic Wilms tumor, is instead related to Ewing sarcoma.
|
17154184 |
2008 |
|
Nephroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Moreover, HACE1 expression was virtually undetectable in the SK-NEP-1 Wilms' tumor cell line and in four of five additional primary Wilms' tumor cases compared with patient-matched normal kidney.
|
15254018 |
2004 |
|
Childhood Kidney Wilms Tumor
|
0.040 |
Biomarker
|
disease |
BEFREE |
Moreover, HACE1 expression was virtually undetectable in the SK-NEP-1 Wilms' tumor cell line and in four of five additional primary Wilms' tumor cases compared with patient-matched normal kidney.
|
15254018 |
2004 |